bioAffinity Technologies' Quarterly CyPath® Lung Sales Double to New Record as Commercial Momentum Continues

bioAffinity Technology reported accelerating commercial sales for its CyPath® Lung diagnostic, with >200% year-over-year growth. The update suggests improving commercial traction but provides no additional financial metrics (e.g., revenue dollars, margins) or guidance changes. Overall, it’s a modestly positive development for near-term sentiment in the company’s fundamentals.

Analysis

bioAffinity Technology reported accelerating commercial sales for its CyPath® Lung diagnostic, with >200% year-over-year growth. The update suggests improving commercial traction but provides no additional financial metrics (e.g., revenue dollars, margins) or guidance changes. Overall, it’s a modestly positive development for near-term sentiment in the company’s fundamentals.